JP2024501022A5 - - Google Patents

Info

Publication number
JP2024501022A5
JP2024501022A5 JP2023539281A JP2023539281A JP2024501022A5 JP 2024501022 A5 JP2024501022 A5 JP 2024501022A5 JP 2023539281 A JP2023539281 A JP 2023539281A JP 2023539281 A JP2023539281 A JP 2023539281A JP 2024501022 A5 JP2024501022 A5 JP 2024501022A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
acid sequence
talen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501022A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062749 external-priority patent/WO2022146654A1/en
Publication of JP2024501022A publication Critical patent/JP2024501022A/ja
Publication of JP2024501022A5 publication Critical patent/JP2024501022A5/ja
Pending legal-status Critical Current

Links

JP2023539281A 2020-12-28 2021-12-10 Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen) Pending JP2024501022A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063131145P 2020-12-28 2020-12-28
US63/131,145 2020-12-28
PCT/US2021/062749 WO2022146654A1 (en) 2020-12-28 2021-12-10 Transcription activator-like effector nucleases (talens) targeting hbv

Publications (2)

Publication Number Publication Date
JP2024501022A JP2024501022A (ja) 2024-01-10
JP2024501022A5 true JP2024501022A5 (enExample) 2024-12-18

Family

ID=80034902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539281A Pending JP2024501022A (ja) 2020-12-28 2021-12-10 Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen)

Country Status (8)

Country Link
US (1) US20240316090A1 (enExample)
EP (1) EP4267740A1 (enExample)
JP (1) JP2024501022A (enExample)
AU (1) AU2021412833A1 (enExample)
CA (1) CA3203442A1 (enExample)
TW (1) TW202242112A (enExample)
UY (1) UY39592A (enExample)
WO (1) WO2022146654A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024211625A1 (en) * 2023-04-07 2024-10-10 Arcturus Therapeutics, Inc. Hbv gene editing
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ,インコーポレーテッド Hbv遺伝子発現のエピジェネティック調節のための組成物および方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1998043702A2 (en) 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
KR101261642B1 (ko) 2004-03-08 2013-05-06 아이커 메디칼 시스템스 인코포레이티드 치료 제제의 전기 매개식 이송을 위한 개선된 장치
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
AU2007313203B2 (en) 2006-10-17 2012-08-16 Vgx Pharmaceuticals, Llc Electroporation devices and methods of using same for electroporation of cells in mammals
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
WO2012093833A2 (en) * 2011-01-03 2012-07-12 Toolgen Incorporation Genome engineering via designed tal effector nucleases
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
JP7461872B2 (ja) 2017-08-17 2024-04-04 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS

Similar Documents

Publication Publication Date Title
Wang et al. HBV genome and life cycle
JP2024502210A5 (enExample)
JP6576904B2 (ja) HIV−1プロウイルスDNAのinvivo切除のための組成物及び方法
JP2021178828A (ja) B型肝炎ウイルス感染に対するRNAi療法
CN104107437B (zh) 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法
CN108136206B (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
CN111372593A (zh) 治疗乙型肝炎感染的方法
Yamamoto et al. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection
JP2025073123A5 (enExample)
Ahmed et al. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
KR101954130B1 (ko) B형 간염 예방 또는 치료용 의약 조성물
JP2023550061A (ja) オリゴヌクレオチド及びその抗b型肝炎とd型肝炎ウイルスにおける応用
JP2023536999A (ja) B型肝炎患者のオリゴヌクレオチド処置
JP2023527875A5 (enExample)
JPWO2018193902A1 (ja) マイクロrnaによるb型肝炎ウイルスに対する抗ウイルス効果
JP2025516583A5 (enExample)
JP2022553375A5 (enExample)
JP2022529481A (ja) B型肝炎ウイルスの増殖を抑制する組成物及びその方法
Martin Perez et al. Enhancing the therapeutic potential of extracellular vesicles using peptide technology
CN113194945B (zh) 环吡酮的抑制hbv核心组装的用途
KR102273071B1 (ko) B형 간염 예방 또는 치료용 조성물
CN114569743B (zh) 肝特异性的基因编辑纳米药物及其制备方法和应用
Chen et al. The changing landscape of gene editing tool delivery in neurological disorders
Zhang et al. Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B
Ely et al. Gene and cell therapy in South Africa: current status and future prospects